Healthcare Industry News: DePuy Synthes
News Release - March 7, 2018
ACTIS(R) Total Hip System from DePuy Synthes is Designed to Improve Initial Implant Stability in Total Hip ReplacementUnique design features, extended range of stem sizes and improved surgical instruments help achieve a precise fit to serve a broader patient population
NEW ORLEANS, March 7, 2018 -- (Healthcare Sales & Marketing Network) -- DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today introduced the ACTIS® Total Hip System in the US at the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans, LA. Recently available on a limited basis, this is the first DePuy Synthes hip system designed to be utilized with tissue-sparing approaches such as the minimally invasive Anterior Approach, as well as traditional approaches in Total Hip Replacement (THR) surgery.
By meeting patients' increasing expectation for returning to function earlier after hip replacement surgery, the ACTIS Hip System supports the need for improved outcomes, better patient satisfaction, and greater value through:
- A stem design that has been shown to improve initial implant stability2,3
- A surgical technique that may enable early patient function1
- Varying stem sizes that help achieve proper fit within the femur to address an increasingly diverse patient population
For more than a decade DePuy Synthes has provided surgeons with enabling technologies, education and implants to advance patient care through the Anterior Approach. Recently, two co-marketing agreements were announced for the ME1000® Surgical Impactor—designed to replace the handheld mallet and provide more consistent clinical outcomes and less surgeon fatigue—and JointPoint®—a non-invasive computer navigation system that allows for intraoperative analysis and digital templating—to provide enabling technologies that integrate with the Anterior Approach and may help improve outcomes. Now, with the addition of the ACTIS Hip System, DePuy Synthes continues its commitment to providing products and solutions that allow surgeons to help patients get back to their everyday lives.
Approximately 11,000 ACTIS Hips have been provided for patients globally. The system continues to roll out broadly in 2018. For more information, see the ACTIS Hip System Design Rationale.
About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies** have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopaedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services.
About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.
*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson's Medical Devices segment.
***Dr. Atul F. Kamath is a consultant to DePuy Synthes Joint Reconstruction.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995, regarding the roll out of the ACTIS® Total Hip System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, Inc., any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; manufacturing difficulties and delays; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
1 Barrett, W., et al. "Prospective Randomized Study of Direct Anterior vs Postero-Lateral Approach for Total Hip Arthroplasty." JOA, 2013 28, pp 1634-1638.
2 Derney, G., Fary, C., Lustig, S., et. Al. "Does a Collar Improve the immediate Stability of Uncemented Femoral Hip Stems in Total Hip Arthroplasty? A Bilateral Comparative Cadaver Study." JOA, 2011 26(8), pp. 1549-1555.
3 Hamburg University Actis Cadaveric Stability Testing. Data on File (Adaptive #103156243).
© DePuy Synthes 2018. All rights reserved.
The third party trademarks used herein are the trademarks of their respective owners.
Source: DePuy Synthes
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.